Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (536)	1/23/2000 12:01:00 PM
From: Biomaven	Respond to of 52153

market capitalization of the entire biotech sector was less than the market cap of Merck Not even nearly true anymore (and I don't think it was true a year ago, either). MRK market cap is about 169 billion. AMGN and DNA together are already 118 billion. All biotechs together by my calculation are about $390 billion. Peter

To: JMarcus who wrote (536)	1/23/2000 5:23:00 PM
From: biowa	Read Replies (1) \| Respond to of 52153

Marc, Actually "quick" back of the envelope calculation for a partly random list of cos. (the traditional big 5, some gx, some mAb, absc, celg and imnx: abgx absc affx amgn bgen calp celg chir cra crgn dna gene genxy genz glgc hgsi idph imnx incy maxy medx mlnm mygn (w/ thanks to LL for saving me the work on gx shares outstanding) yields a mkt cap as of Friday's close of $186B vs. MRK's $167M Even more interesting, Larry's gx list has a mkt cap 25% of MRK's. Without a single clinical product (there may be a couple diagnostics in there, and of course there's the info they sell). biowa